Member Info for RoyRoy

I cant recal John Shaw (or company releases) mentioning dividends before but I'm by no means the fountain of knowledge here.

My opinion* is that this is a company which would pay a dividend should they turn enough profit to do so. The reason is that John Shaw knows that the shareholders saved this company. Last year, they had cash for a couple of months, debt, and although they had orders , they didn't have the capital to sustain production. The placing changed everything.

One of the reasons I'm invested here is that having been so close to collapse (okay, going private and perhpas getting sold off cheap), they've learned a lot and now appear to be running a very tight ship. They'll be making profit before you can learn to say poly itaconate (without pause) and my feeling is they'll reward those that bought in during dark times.

*Complete unfounded opinion disclaimer

Exactly.

Sell (ie top slice) if you want but don't expect to buy back in with ease...

Curious.... and maybe positive news but when i tried just there, I can sell every ITX share I own at 6p ... but I get "No trade" when I try and buy £40 worth...

An interesting conversation with George Katzaros, founder of solar energy company Verditek and co-founder of sustainable housing provider Zero Watt Homes, about his career to date. They also discuss developments and trends in the clean technology and housing markets.
https://pca.st/episode/bb2c435f-cef5-4124-b234-c2cb64737f14

Thanks Saseefeldt,

I'm interested to hear your thoughts on "crap company, leadership and product."
What makes the company crap and why do you say the same about the product?

As well as...

Zinador™ 35L
Zinador 35L is an 85% bio-based odour neutralising active with 75% higher zinc than Zinador 22L. Zinador 35L exhibits improved compatibility with high salt and high surfactant formulations over Zinador 22L. With a significant increase in zinc level, Zinador 35L showcases excellent odour neutralising properties against a broad range of odours. Suitable for a wide range of applications, Zinador 35L stands out in laundry formulations with its proven ease of formulation and lower cost in use compared to other zinc-based odour neutralisers. Developed and produced with Itaconix polymer technology.
https://www.crodahomecare.com/en-gb/products-and-applications/product-finder/product/5416/Zinador_1_35L?pageEvent=db1bc698-5c30-4be7-b130-0e2b5fb5b7d7

Apologies i this has already been posted but Itaconix even get a mention in this one...! First time I've seen that.

Zinador™ 22L
Zinador 22L is a 100% bio-based odour neutraliser that has proven to be effective against a broad range of household and industrial odours. Independent testing by trained panellists has demonstrated the effectiveness of Zinador 22L against most common malodours. It requires no emulsifiers or chelators to formulate, making it cost effective and very easy-to-use. Developed and produced using Itaconix polymer technology.
https://www.crodahomecare.com/en-gb/products-and-applications/product-finder/product/2618/Zinador_1_22L#tab-collapse-performance-highlights

Indeed. Cheap for good reason tho as these guys are still looking sales whereas EQT have had a steady stream of contracts in recent months.

They have huge potential tho and as others have pointed out, it wouldn't take much for the share price to rise when the sales team start to get signatures. By my (very amatuer) calcs, installing panels on just one fleet of 1000 trucks and would bring us to almost break even. In sunny Australia, there are roughly 400,000 (rigid and articulated) trucks which could potentially benefit from Verditek's integrated solar-diesel solution. That's a (very, roughly) +£500m market.

And then there's still quite sunny Europe... etc etc
And then there's oil and gas, telecoms, real estate, carports, bus and tram stops, remote military, disaster relief, marine...and consumer.

I repeat ... potential == huge.

This is true, but the opposite is also the case; it won't take much for this share to rise back up.

This company has a really great product. It's innovative, cost effective, and highly versitle. The number of sectors and applications where this technology could be deployed is huge.

With a market cap of only £25mil, in the rapidly expanding renewables market, this company has a lot of growth potential!

Not wanting to ruffle any feathers but i think it's a mistake to speak of some trying to "make a quick buck today".

There are many LTH in here who deserve to take some rewards afte a long, long wait. (Some maybe even cutting their losses at 6p!). I think we should also be thankful for the increaased trading volume as that it what often give these tiny companies share price a big boost. It wasn't that long ago when we'd literally see circa 6 share trades a day....day after day. (Yesterday we saw something in excess of 500.)

Having said that, I love this company and have been inbig for a while. I have no intention of taking profits yet and am happy to wait for this company to mature and reward me with much, much greater returns.

I think there are a number of factors but perhaps one is the lack of (RNS) news today. On a busy day, there would be loads of opportunites in which to re-invest yesterdays wonderful gains of ITX and the share price could have easily dropped 20-25% from the off.

Well flowerpot999, perhaps there is this one...
https://www.lse.co.uk/ShareChat.asp?ShareTicker=ITX&share=Itaconix-Plc

Despite the recent rise from 2.5p -> 6p, this company still only has a MCAP of £26m and has shown rapid growth over the past year. Expecting unaudited accounts for 2020 within the coming days/weeks showing fantastic year on year results.
(Some research: https://www.youtube.com/watch?v=o7HDRpjANNw)

Yes Saxo, very good. But the BBC was the reference and they only published the article 18 hours ago.

I doubt whether any of us (you included Saxo), have as much data as the WHO on such issues. There may be hundreds of potential treatments to Covid and they cannot test them all. I love Faron but they do not yet have any approved drugs in the market place and as such have no track record when compared with the big boys. (I'm not here to defend big Pharm!)

This is one of the more civilised boards on lse but I think we could all do with a little more perspective. The world (health organisation) does not revolve around you, your Faron stock, or how much you believe Traumakine is the best treatrment for Covid. A global pandemic is an incredibly complicated scenario to deal with and I think all this WHO hating is petty, immature, and pointless. Perhaps we would all have been happier if Faron had raised £10M (through a placing) to run it's own trial...?

To conclude, I do think Faron have a promising future in Traumakine and Clevergen and will stay upbeat and foccussed on the long term. Festive cheer and good health to you all.

https://www.bbc.co.uk/news/health-54832563

"Interferon can be given as a treatment, but a World Health Organisation clinical trial concluded that it did not help very sick patients. However, Prof Casanova said the timing was important.

He explained: “I hope that if given in the first two, three, four days of infection, the interferon would work, because it essentially would provide the molecule that the [patient] does not produce by himself or by herself.”

Mil09, I'm not against your post...it just doesn't make sense to me.

You say you got in 2 years ago and have been adding when you can... This company was never going to be making a profit in the last few years. In all the recent presentations, JS talks about how 2017-2019 was mostly about sending out samples. The samples are for prospective customers to gauge whether or not, ITX products might be good additions to their products. They've send out hundreds of these testers. Now, since these testers went out, interested customers have been working with ITX to tailor these ingredients to work specifically for their products. The time is takes from sample to production can be around a year.

At this juncture, more and more customers are coming back with interest, more and more tailoring is happening, and customers are starting to put in serious orders. It's the final step which brings in the money and that is why, as Wololol writes, revenue is really ramping up.

In all the time over the past few years, I'd say now is the least best time to quit.

Yes, a far better performane from John Shaw this time.

As for the numbers, if I hearing him right. revenue for this year could be around $2.9M (H1 = 1.1, H2 = 1.8) which would be +124% on 2019...and, unless I'm mistaken, very close to breaking even. Continuing the amateur maths, am i right in thinking ITX are looking for an extra ~$1.36M on last years revenues? These numbers would give them +$1.6M on last year (minus cost of sales of course).

Now, I'm no expert so this might well be bunkum but could the MM's be filling an order here...?
The spread is massive which is keeping the share price down and there's been loads of buys at 2.05...

Someone with greater knowledge than me (and L2 visibility) can debunk this one :)

Indeed...

What are you talking about man? Do you think ITX are just making up the numbers in the 2019 Full results and the 2020 interims? Would you be happier if he was reporting an 80% increase in revenue as "...a bit c***" and saying "...we should be doing better..."? Honestly, there's fact and then there's nonsense.

Having said that, I don't think John Shaws performance yesterday was good. He made a muddle of quite a few things...not least the "Potential revenue" question. I just think he was trying to be as open and honest as possible. This is a company that is fundamentally scientific and he was taking that cautious approach in his replies. I'm putting a large part of the share price dip down to that tbh.

Medium term, I'm not worried in the slightest. I beleive this company has many years of solid growth.

For me, this was the most interesting part...

"Itaconix is at a new stage of long-term revenue growth and value creation. The expanding customer base for our current products is generating recurring revenues and financial performance that places us on a discernible path to achieve our near-term goal of sustained revenue growth to reach profitability. We have a pipeline of active customer projects to reach beyond this goal and look firmly to the future with continued optimism."